Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention

Objective We hypothesized that genetic variation affects responsiveness to 17-alpha hydroxyprogesterone caproate (17P) for recurrent preterm birth prevention. Study Design Women of European ancestry with ≥1 spontaneous singleton preterm birth at

Saved in:
Bibliographic Details
Published in:American journal of obstetrics and gynecology 2014-04, Vol.210 (4), p.321.e1-321.e21
Main Authors: Manuck, Tracy A., MD, Watkins, W. Scott, MS, Moore, Barry, MS, Esplin, M. Sean, MD, Varner, Michael W., MD, Jackson, G. Marc, MD, Yandell, Mark, PhD, Jorde, Lynn, PhD
Format: Article
Language:English
Subjects:
17 alpha-Hydroxyprogesterone Caproate
Case-Control Studies
Estrogen Antagonists - administration & dosage
Exome
Female
Genetic Variation
Humans
Hydroxyprogesterones - administration & dosage
Nitric Oxide Synthase - genetics
Nitric Oxide Synthase Type I - genetics
Obstetrics and Gynecology
Pharmacogenetics
Pregnancy
Premature Birth - prevention & control
Prospective Studies
Secondary Prevention
Sequence Analysis, DNA - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective We hypothesized that genetic variation affects responsiveness to 17-alpha hydroxyprogesterone caproate (17P) for recurrent preterm birth prevention. Study Design Women of European ancestry with ≥1 spontaneous singleton preterm birth at
ISSN:0002-9378
1097-6868
1097-6868
DOI:10.1016/j.ajog.2014.01.013